Joseph Ciccolini

List of Publications by Citations

148 papers	3,265 citations	33 h-index	50 g-index
159 ext. papers	3,892 ext. citations	4.9 avg, IF	5.3 L-index

#	Paper	IF	Citations
148	Propranolol potentiates the anti-angiogenic effects and anti-tumor efficacy of chemotherapy agents: implication in breast cancer treatment. *Oncotarget*, **2011**, 2, 797-809	3.3	154
147	Computational oncology--mathematical modelling of drug regimens for precision medicine. *Nature Reviews Clinical Oncology*, **2016**, 13, 242-54	19.4	133
146	Clinical Pharmacokinetics and Pharmacodynamics of Immune Checkpoint Inhibitors. *Clinical Pharmacokinetics*, **2019**, 58, 835-857	6.2	111
145	Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspective. *Cancer Chemotherapy and Pharmacology*, **2016**, 78, 1-12	3.5	99
144	Cytidine deaminase residual activity in serum is a predictive marker of early severe toxicities in adults after gemcitabine-based chemotherapies. *Journal of Clinical Oncology*, **2010**, 28, 160-5	2.2	94
143	Pharmacogenetics of capecitabine in advanced breast cancer patients. *Clinical Cancer Research*, **2006**, 12, 5496-502	12.9	91
142	Mathematical Modeling of Cancer Immunotherapy and Its Synergy with Radiotherapy. *Cancer Research*, **2016**, 76, 4931-40	10.1	84
141	Challenges, expectations and limits for nanoparticles-based therapeutics in cancer: a focus on nano-albumin-bound drugs. *Critical Reviews in Oncology/Hematology*, **2013**, 88, 504-13	7	74
140	A rapid and inexpensive method for anticipating severe toxicity to fluorouracil and fluorouracil-based chemotherapy. *Therapeutic Drug Monitoring*, **2006**, 28, 678-85	3.2	73
139	Increased cytotoxicity and bystander effect of 5-fluorouracil and 5-deoxy-5-fluorouridine in human colorectal cancer cells transfected with thymidine phosphorylase. *British Journal of Cancer*, **1999**, 80, 1726-33	8.7	73
138	Mathematical modeling of tumor growth and metastatic spreading: validation in tumor-bearing mice. *Cancer Research*, **2014**, 74, 6397-407	10.1	71
137	Molecular mechanisms underlying the interaction between ZD1839 (Iressa) and cisplatin/5-fluorouracil. *British Journal of Cancer*, **2003**, 89, 585-92	8.7	69
136	Optimization of trans-Resveratrol bioavailability for human therapy. *Biochimie*, **2013**, 95, 1233-8	4.6	67
135	Routine dihydropyrimidine dehydrogenase testing for anticipating 5-fluorouracil-related severe toxicities: hype or hope?. *Clinical Colorectal Cancer*, **2010**, 9, 224-8	3.8	66
134	Liposome-encapsulated anticancer drugs: still waiting for the magic bullet?. *Current Medicinal Chemistry*, **2009**, 16, 4361-71	4.3	66
133	A simple and rapid high-performance liquid chromatographic (HPLC) method for 5-fluorouracil (5-FU) assay in plasma and possible detection of patients with impaired dihydropyrimidine dehydrogenase (DPD) activity. *Journal of Clinical Pharmacy and Therapeutics*, **2004**, 29, 307-15	2.2	65
132	DPD-based adaptive dosing of 5-FU in patients with head and neck cancer: impact on treatment efficacy and toxicity. *Cancer Chemotherapy and Pharmacology*, **2011**, 67, 49-56	3.5	58

131	Antiproliferative effect of ascorbic acid is associated with the inhibition of genes necessary to cell cycle progression. *PLoS ONE*, **2009**, 4, e4409	3.7	57
130	Profiling dihydropyrimidine dehydrogenase deficiency in patients with cancer undergoing 5-fluorouracil/capecitabine therapy. *Clinical Colorectal Cancer*, **2006**, 6, 288-96	3.8	57
129	Involvement of microtubules and mitochondria in the antagonism of arsenic trioxide on paclitaxel-induced apoptosis. *Biochemical Pharmacology*, **2002**, 63, 1831-42	6	55
128	Integrating pharmacogenetics into gemcitabine dosing--time for a change?. *Nature Reviews Clinical Oncology*, **2011**, 8, 439-44	19.4	53
127	Metronomic reloaded: Theoretical models bringing chemotherapy into the era of precision medicine. *Seminars in Cancer Biology*, **2015**, 35, 53-61	12.7	50
126	Role of cytidine deaminase in toxicity and efficacy of nucleosidic analogs. *Expert Opinion on Drug Metabolism and Toxicology*, **2015**, 11, 665-72	5.5	45
125	Toxic death case in a patient undergoing gemcitabine-based chemotherapy in relation with cytidine deaminase downregulation. *Pharmacogenetics and Genomics*, **2007**, 17, 841-4	1.9	45
124	Toxic death-case after capecitabine + oxaliplatin (XELOX) administration: probable implication of dihydropyrimidine deshydrogenase deficiency. *Cancer Chemotherapy and Pharmacology*, **2006**, 58, 272-5	3.5	38
123	Personalized medicine in oncology: where have we come from and where are we going?. *Pharmacogenomics*, **2013**, 14, 931-9	2.6	36
122	Optimizing Druggability through Liposomal Formulations: New Approaches to an Old Concept. *ISRN Pharmaceutics*, **2012**, 2012, 738432		36
121	High-dose methotrexate in adults with osteosarcoma: a population pharmacokinetics study and validation of a new limited sampling strategy. *Anti-Cancer Drugs*, **2008**, 19, 267-73	2.4	36
120	ZD1839 (Iressa) modifies the activity of key enzymes linked to fluoropyrimidine activity: rational basis for a new combination therapy with capecitabine. *Clinical Cancer Research*, **2003**, 9, 4735-42	12.9	35
119	Early severe toxicities after capecitabine intake: possible implication of a cytidine deaminase extensive metabolizer profile. *Cancer Chemotherapy and Pharmacology*, **2009**, 63, 1177-80	3.5	34
118	Thymidine phosphorylase and fluoropyrimidines efficacy: a Jekyll and Hyde story. *Anti-Cancer Agents in Medicinal Chemistry*, **2004**, 4, 71-81		34
117	Beating the odds: efficacy and toxicity of dihydropyrimidine dehydrogenase-driven adaptive dosing of 5-FU in patients with digestive cancer. *British Journal of Clinical Pharmacology*, **2016**, 81, 124-30	3.8	33
116	Rapid deaminator status is associated with poor clinical outcome in pancreatic cancer patients treated with a gemcitabine-based regimen. *Pharmacogenomics*, **2013**, 14, 1047-51	2.6	32
115	A simple and rapid LC-MS/MS method for therapeutic drug monitoring of cetuximab: a GPCO-UNICANCER proof of concept study in head-and-neck cancer patients. *Scientific Reports*, **2017**, 7, 2714	4.9	32
114	Population modeling of tumor growth curves and the reduced Gompertz model improve prediction of the age of experimental tumors. *PLoS Computational Biology*, **2020**, 16, e1007178	5	30

113	Metronomics chemotherapy: time for computational decision support. *Cancer Chemotherapy and Pharmacology*, **2014**, 74, 647-52	3.5	30
112	Docetaxel-trastuzumab stealth immunoliposome: development and in vitro proof of concept studies in breast cancer. *International Journal of Nanomedicine*, **2018**, 13, 3451-3465	7.3	28
111	Pharmacokinetics variability: Why nanoparticles are not just magic-bullets in oncology. *Critical Reviews in Oncology/Hematology*, **2018**, 129, 1-12	7	28
110	Therapeutic drug monitoring for dose individualization of Cisplatin in testicular cancer patients based upon total platinum measurement in plasma. *Therapeutic Drug Monitoring*, **2006**, 28, 532-9	3.2	28
109	Pharmacokinetics and Pharmacodynamics-Based Mathematical Modeling Identifies an Optimal Protocol for Metronomic Chemotherapy. *Cancer Research*, **2017**, 77, 4723-4733	10.1	27
108	Severe or lethal toxicities upon capecitabine intake: is DPYD genetic polymorphism the ideal culprit?. *Trends in Pharmacological Sciences*, **2007**, 28, 597-8	13.2	27
107	5-FU-induced neurotoxicity in cancer patients with profound DPD deficiency syndrome: a report of two cases. *Cancer Chemotherapy and Pharmacology*, **2011**, 68, 823-6	3.5	25
106	Response of endothelial cells to a dual tyrosine kinase receptor inhibition combined with irradiation. *Molecular Cancer Therapeutics*, **2005**, 4, 1962-71	6.1	23
105	Sudden death related to toxicity in a patient on capecitabine and irinotecan plus bevacizumab intake: pharmacogenetic implications. *Journal of Clinical Oncology*, **2012**, 30, e41-4	2.2	22
104	Model driven optimization of antiangiogenics + cytotoxics combination: application to breast cancer mice treated with bevacizumab + paclitaxel doublet leads to reduced tumor growth and fewer metastasis. *Oncotarget*, **2017**, 8, 23087-23098	3.3	22
103	All You Need to Know About Genetic Testing for Patients Treated With Fluorouracil and Capecitabine: A Practitioner-Friendly Guide. *JCO Oncology Practice*, **2020**, 16, 793-798	2.3	21
102	Lack of contribution of dihydrofluorouracil and alpha-fluoro-beta-alanine to the cytotoxicity of 5&deoxy-5-fluorouridine on human keratinocytes. *Anti-Cancer Drugs*, **2004**, 15, 969-74	2.4	20
101	Biodistribution, tumor uptake and efficacy of 5-FU-loaded liposomes: why size matters. *Pharmaceutical Research*, **2014**, 31, 2677-84	4.5	19
100	Dose individualization of carboplatin after a 120-hour infusion schedule: higher dose intensity but fewer toxicities. *Therapeutic Drug Monitoring*, **2006**, 28, 212-8	3.2	19
99	From 3D spheroids to tumor bearing mice: efficacy and distribution studies of trastuzumab-docetaxel immunoliposome in breast cancer. *International Journal of Nanomedicine*, **2018**, 13, 6677-6688	7.3	19
98	A phase Ia/Ib clinical trial of metronomic chemotherapy based on a mathematical model of oral vinorelbine in metastatic non-small cell lung cancer and malignant pleural mesothelioma: rationale and study protocol. *BMC Cancer*, **2016**, 16, 278	4.8	18
97	Population pharmacokinetics of etoposide: application to therapeutic drug monitoring. *Therapeutic Drug Monitoring*, **2002**, 24, 709-14	3.2	18
96	Mathematical modeling for Phase I cancer trials: A study of metronomic vinorelbine for advanced non-small cell lung cancer (NSCLC) and mesothelioma patients. *Oncotarget*, **2017**, 8, 47161-47166	3.3	17

95	Revisiting Dosing Regimen Using Pharmacokinetic/Pharmacodynamic Mathematical Modeling: Densification and Intensification of Combination Cancer Therapy. *Clinical Pharmacokinetics*, **2016**, 55, 1015-25	6.2	16
94	A new mathematical model for optimizing the combination between antiangiogenic and cytotoxic drugs in oncology. *Comptes Rendus Mathematique*, **2012**, 350, 23-28	0.4	16
93	High-resolution melting analysis of sequence variations in the cytidine deaminase gene (CDA) in patients with cancer treated with gemcitabine. *Therapeutic Drug Monitoring*, **2010**, 32, 53-60	3.2	16
92	Alpha-hederin potentiates 5-FU antitumor activity in human colon adenocarcinoma cells. *Phytotherapy Research*, **2008**, 22, 1299-302	6.7	16
91	Development of stealth liposome formulation of 2Ɵdeoxyinosine as 5-fluorouracil modulator: in vitro and in vivo study. *Pharmaceutical Research*, **2005**, 22, 2051-7	4.5	16
90	Plasminogen Activator System and Breast Cancer: Potential Role in Therapy Decision Making and Precision Medicine. *Biomarker Insights*, **2016**, 11, 105-11	3.5	15
89	CDA deficiency as a possible culprit for life-threatening toxicities after cytarabine plus 6-mercaptopurine therapy: pharmacogenetic investigations. *Pharmacogenomics*, **2012**, 13, 393-7	2.6	15
88	Genotype-based methods for anticipating gemcitabine-related severe toxicities may lead to false-negative results. *Journal of Clinical Oncology*, **2007**, 25, 4855; author reply 4855-6	2.2	15
87	COVID-19 vaccine race: watch your step for cancer patients. *British Journal of Cancer*, **2021**, 124, 860-861	8.7	15
86	Transmission of apoptosis in human colorectal tumor cells exposed to capecitabine, Xeloda, is mediated via Fas. *Molecular Cancer Therapeutics*, **2002**, 1, 923-7	6.1	15
85	Drug repurposing in malignant pleural mesothelioma: a breath of fresh air?. *European Respiratory Review*, **2018**, 27,	9.8	14
84	Selection of the best blood compartment to measure cytidine deaminase activity to stratify for optimal gemcitabine or cytarabine treatment. *Nucleosides, Nucleotides and Nucleic Acids*, **2014**, 33, 403-12	1.4	14
83	In Vivo Bioluminescence Tomography for Monitoring Breast Tumor Growth and Metastatic Spreading: Comparative Study and Mathematical Modeling. *Scientific Reports*, **2016**, 6, 36173	4.9	14
82	Turning cold tumors into hot tumors: harnessing the potential of tumor immunity using nanoparticles. *Expert Opinion on Drug Metabolism and Toxicology*, **2018**, 14, 1139-1147	5.5	14
81	Cytotoxic effects of haplamine and its major metabolites on human cancer cell lines. *Planta Medica*, **2008**, 74, 1265-8	3.1	13
80	Dose Effect of Rhenium (I)-diselenoether as Anticancer Drug in Resistant Breast Tumor-bearing Mice After Repeated Administrations. *Anticancer Research*, **2016**, 36, 6051-6057	2.3	13
79	Monitoring of the intracellular activation of 5-fluorouracil to deoxyribonucleotides in HT29 human colon cell line: application to modulation of metabolism and cytotoxicity study. *Fundamental and Clinical Pharmacology*, **2000**, 14, 147-54	3.1	12
78	FFCD-1004 Clinical Trial: Impact of Cytidine Deaminase Activity on Clinical Outcome in Gemcitabine-Monotherapy Treated Patients. *PLoS ONE*, **2015**, 10, e0135907	3.7	12

77	UPFRONT DPD DEFICIENCY DETECTION TO SECURE 5-FU ADMINISTRATION: PART 2- APPLICATION TO HEAD-AND-NECK CANCER PATIENTS. *Clinical Cancer Drugs*, **2017**, 4, 122-128	0.2	12
76	CDA as a predictive marker for life-threatening toxicities in patients with AML treated with cytarabine. *Blood Advances*, **2018**, 2, 462-469	7.8	12
75	Therapeutic Drug Monitoring of Carboplatin in High-Dose Protocol (TI-CE) for Advanced Germ Cell Tumors: Pharmacokinetic Results of a Phase II Multicenter Study. *Clinical Cancer Research*, **2017**, 23, 7171-7179	12.9	11
74	In vitro and in vivo evaluation of lipofufol, a new triple stealth liposomal formulation of modulated 5-fu: impact on efficacy and toxicity. *Pharmaceutical Research*, **2013**, 30, 1281-90	4.5	11
73	Population pharmacokinetic analysis of 5-FU and 5-FDHU in colorectal cancer patients: search for biomarkers associated with gastro-intestinal toxicity. *Current Topics in Medicinal Chemistry*, **2012**, 12, 1713-9	3	11
72	Genetic and biochemical modulation of 5-fluorouracil through the overexpression of thymidine kinase: an in-vitro study. *Anti-Cancer Drugs*, **2006**, 17, 463-70	2.4	11
71	Seek and destroy: improving PK/PD profiles of anticancer agents with nanoparticles. *Expert Review of Clinical Pharmacology*, **2018**, 11, 599-610	3.8	11
70	Pharmacogenetics and breast cancer management: current status and perspectives. *Expert Opinion on Drug Metabolism and Toxicology*, **2015**, 11, 719-29	5.5	9
69	DPD deficiency in patients treated with fluorouracil. *Lancet Oncology, The*, **2015**, 16, 1574-6	21.7	9
68	Yin and yang of cytidine deaminase roles in clinical response to azacitidine in the elderly: a pharmacogenetics tale. *Pharmacogenomics*, **2015**, 16, 1907-12	2.6	9
67	Positive interaction between lapatinib and capecitabine in human breast cancer models: study of molecular determinants. *Fundamental and Clinical Pharmacology*, **2012**, 26, 530-7	3.1	9
66	A well-tolerated 5-FU-based treatment subsequent to severe capecitabine-induced toxicity in a DPD-deficient patient. *British Journal of Clinical Pharmacology*, **2008**, 65, 966-70	3.8	9
65	Revisiting Bevacizumab + Cytotoxics Scheduling Using Mathematical Modeling: Proof of Concept Study in Experimental Non-Small Cell Lung Carcinoma. *CPT: Pharmacometrics and Systems Pharmacology*, **2018**, 7, 42-50	4.5	9
64	Improving efficacy of the combination between antiangiogenic and chemotherapy: Time for mathematical modeling support. *Proceedings of the National Academy of Sciences of the United States of America*, **2015**, 112, E3453	11.5	8
63	Towards Rational Cancer Therapeutics: Optimizing Dosing, Delivery, Scheduling, and Combinations. *Clinical Pharmacology and Therapeutics*, **2020**, 108, 458-470	6.1	8
62	Gender, cytidine deaminase, and 5-aza/decitabine--letter. *Clinical Cancer Research*, **2013**, 19, 3105	12.9	8
61	Phase I and pharmacokinetic study of escalating dose of docetaxel administered with granulocyte colony-stimulating factor support in adult advanced solid tumors. *Clinical Cancer Research*, **2003**, 9, 102-8	12.9	8
60	Cancer Immunotherapy Dosing: A Pharmacokinetic/Pharmacodynamic Perspective. *Vaccines*, **2020**, 8,	5.3	7

59	Letter to the editor: pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism. *European Journal of Clinical Pharmacology*, **2010**, 66, 959-60	2.8	7
58	Taxotere-5⊖deoxy-5-fluorouridine combination on hormone-refractory human prostate cancer cells. *Anti-Cancer Drugs*, **2005**, 16, 309-16	2.4	7
57	Trastuzumab-induced cardiotoxicity: is it a personalized risk?. *Current Drug Targets*, **2014**, 15, 1200-4	3	7
56	Enhanced Antisense Oligonucleotide Delivery Using Cationic Liposomes Grafted with Trastuzumab: A Proof-of-Concept Study in Prostate Cancer. *Pharmaceutics*, **2020**, 12,	6.4	7
55	Monoclonal antibodies for treating gastric cancer: promises and pitfalls. *Expert Opinion on Biological Therapy*, **2016**, 16, 759-69	5.4	6
54	A CDD polymorphism as predictor of capecitabine-induced hand-foot syndrome--letter. *Clinical Cancer Research*, **2012**, 18, 317	12.9	6
53	Validation of a simple HPLC method for assay of haplamine and its metabolites in plasma suitable for pharmacokinetic application in rats. *Biomedical Chromatography*, **2008**, 22, 125-30	1.7	6
52	Lethal toxicities after capecitabine intake in a previously 5-FU-treated patient: why dose matters with dihydropryimidine dehydrogenase deficiency. *Pharmacogenomics*, **2019**, 20, 931-938	2.6	5
51	A Simple and Rapid UPLC-UV Method for Detecting DPD Deficiency in Patients With Cancer. *Clinical and Translational Science*, **2020**, 13, 761-768	4.9	5
50	A simple and rapid liquid chromatography-mass spectrometry method to assay cabozantinib in plasma: Application to therapeutic drug monitoring in patients with renal cell carcinoma. *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences*, **2020**, 1138, 121968	3.2	5
49	Women at a Disadvantage in Fluorouracil Treatment. *JAMA Oncology*, **2016**, 2, 829-30	13.4	5
48	Effect of several compounds on biliary excretion of paclitaxel and its metabolites in guinea-pigs. *Anti-Cancer Drugs*, **2005**, 16, 675-82	2.4	5
47	Lethal toxicity after administration of azacytidine: implication of the cytidine deaminase-deficiency syndrome. *Pharmacogenetics and Genomics*, **2015**, 25, 317-21	1.9	5
46	Tumor uptake and associated greater efficacy of anti-Her2 immunoliposome does not rely on Her2 expression status: study of a docetaxel-trastuzumab immunoliposome on Her2+ breast cancer model (SKBR3). *Anti-Cancer Drugs*, **2020**, 31, 463-472	2.4	5
45	Nucleoside analogs: ready to enter the era of precision medicine?. *Expert Opinion on Drug Metabolism and Toxicology*, **2016**, 12, 865-77	5.5	5
44	Simultaneous determination of cytosine arabinoside and its metabolite uracil arabinoside in human plasma by LC-MS/MS: Application to pharmacokinetics-pharmacogenetics pilot study in AML patients. *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences*, **2019**, 1126-1127, 121770	3.2	4
43	Optimal Scheduling of Bevacizumab and Pemetrexed/Cisplatin Dosing in Non-Small Cell Lung Cancer. *CPT: Pharmacometrics and Systems Pharmacology*, **2019**, 8, 577-586	4.5	4
42	Eradication of T315I mutation in chronic myeloid leukemia without third-generation tyrosine kinase inhibitor: a case report. *Pharmacogenomics*, **2015**, 16, 677-9	2.6	4

41	Mechanistic Learning for Combinatorial Strategies With Immuno-oncology Drugs: Can Model-Informed Designs Help Investigators?. *JCO Precision Oncology*, **2020**, 4, 486-491	3.6	4
40	Is There Any Room for Pharmacometrics With Immuno-Oncology Drugs? Input from the EORTC-PAMM Course on Preclinical and Early-phase Clinical Pharmacology. *Anticancer Research*, **2019**, 39, 3419-3422	2.3	4
39	Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: The multiparametric approach is not convincing. *Seminars in Oncology*, **2017**, 44, 159-160	5.5	4
38	Successful treatment of post-transplant Epstein-Barr virus-related meningoencephalitis by intravenous rituximab monotherapy. *Leukemia and Lymphoma*, **2012**, 53, 2063-5	1.9	4
37	Reply to E. Giovannetti et al. *Journal of Clinical Oncology*, **2010**, 28, e223-e225	2.2	4
36	Can CDA deficiency explain tumour lysis syndrome in a child with neuroblastoma receiving gemcitabine?. *Pediatric Blood and Cancer*, **2010**, 54, 781-2	3	4
35	Synergistic cytotoxic interaction in hormone-refractory prostate cancer with the triple combination docetaxel-erlotinib and 5-fluoro-5⊖deoxyuridine. *Anti-Cancer Drugs*, **2006**, 17, 807-13	2.4	4
34	Like a Rolling Stone: Sting-Cgas Pathway and Cell-Free DNA as Biomarkers for Combinatorial Immunotherapy. *Pharmaceutics*, **2020**, 12,	6.4	4
33	Unraveling the complexity of therapeutic drug monitoring for monoclonal antibody therapies to individualize dose in oncology. *Pharmacology Research and Perspectives*, **2021**, 9, e00757	3.1	4
32	Pharmacodynamic Therapeutic Drug Monitoring for Cancer: Challenges, Advances, and Future Opportunities. *Therapeutic Drug Monitoring*, **2019**, 41, 142-159	3.2	4
31	Can cytidine deaminase be used as predictive biomarker for gemcitabine toxicity and response?. *British Journal of Clinical Pharmacology*, **2019**, 85, 1213-1214	3.8	3
30	Deciphering the response and resistance to immune-checkpoint inhibitors in lung cancer with artificial intelligence-based analysis: when PIONeeR meets QUANTIC. *British Journal of Cancer*, **2020**, 123, 337-338	8.7	3
29	Recipient/donor contradictory genotypes with impact on drug pharmacogenetics after liver transplant: a deadly gift?. *Pharmacogenetics and Genomics*, **2014**, 24, 527-9	1.9	3
28	Potential Role of Exosomes in the Chemoresistance to Gemcitabine and Nab-Paclitaxel in Pancreatic Cancer.. *Diagnostics*, **2022**, 12,	3.8	3
27	Abstract 3677: Model-based optimization of combined antiangiogenic + cytotoxics modalities: application to the bevacizumab-paclitaxel association in breast cancer models **2014**,		3
26	Population Pharmacokinetics of Gemcitabine and dFdU in Pancreatic Cancer Patients Using an Optimal Design, Sparse Sampling Approach. *Therapeutic Drug Monitoring*, **2017**, 39, 290-296	3.2	2
25	Pharmacogenetics and pharmacokinetics modeling of unexpected and extremely severe toxicities after sorafenib intake. *Pharmacogenomics*, **2020**, 21, 173-179	2.6	2
24	An alternative parameter for early forecasting clinical response in NSCLC patients during radiotherapy: proof of concept study. *British Journal of Radiology*, **2016**, 89, 20160061	3.4	2

23	Estimation of Unbound Carboplatin Clearance From Total Plasma Concentrations as a Means of Facilitating Therapeutic Drug Monitoring. *Therapeutic Drug Monitoring*, **2019**, 41, 66-74	3.2	2
22	Pharmacokinetics and pharmacogenetics of liposomal cytarabine in AML patients treated with CPX-351. *Journal of Controlled Release*, **2021**, 338, 244-252	11.7	2
21	PRIMUM NON NOCERE: now and again an echo of DPD with capecitabine. *Cancer Chemotherapy and Pharmacology*, **2017**, 80, 1265-1266	3.5	1
20	100% human monoclonal antibodies in oncology: hype or breakthrough?. *Current Topics in Medicinal Chemistry*, **2012**, 12, 1643-8	3	1
19	Population Modeling of Tumor Growth Curves, the Reduced Gompertz Model and Prediction of the Age of a Tumor. *Lecture Notes in Computer Science*, **2019**, 87-97	0.9	1
18	Multicentric phase II trial of TI-CE high-dose chemotherapy with therapeutic drug monitoring of carboplatin in patients with relapsed advanced germ cell tumors. *Cancer Medicine*, **2021**, 10, 2250-2258	4.8	1
17	Clinical-Based vs. Model-Based Adaptive Dosing Strategy: Retrospective Comparison in Real-World mRCC Patients Treated with Sunitinib. *Pharmaceuticals*, **2021**, 14,	5.2	1
16	Cross-Validation of a Multiplex LC-MS/MS Method for Assaying mAbs Plasma Levels in Patients with Cancer: A GPCO-UNICANCER Study. *Pharmaceuticals*, **2021**, 14,	5.2	1
15	Detecting DPD deficiency: when perfect is the enemy of good. *Cancer Chemotherapy and Pharmacology*, **2021**, 87, 717-719	3.5	0
14	Mechanistic models for hematological toxicities: Small is beautiful. *CPT: Pharmacometrics and Systems Pharmacology*, **2021**, 10, 396-398	4.5	0
13	Ang1 and Tie2 are predictive biomarkers for bevacizumab-letter. *Clinical Cancer Research*, **2015**, 21, 934	12.9	
12	Pharmacokinetics and Pharmacogenetics of Metronomics **2016**, 189-207		
11	La pharmacogétique constitutionnelle est-elle le chaîon manquant de la médecine personnalisè en oncologie ?. *Bulletin Du Cancer*, **2012**, 99, 903-905	2.4	
10	Research Highlights: Highlights from the latest articles in pharmacogenomics. *Pharmacogenomics*, **2013**, 14, 1137-1139	2.6	
9	Adaptive dosing of sunitinib in a metastatic renal cell carcinoma patient: when in silico modeling helps to go quicker to the point.. *Cancer Chemotherapy and Pharmacology*, **2022**, 89, 565	3.5	
8	Dihydropyrimidine Dehydrogenase (Dpyd) Gene Polymorphism: Portrait of a Serial Killer **2008**, 249-265		
7	The association between adverse events and outcome under checkpoint inhibitors: Where is the deal?. *Translational Oncology*, **2021**, 14, 100952	4.9	
6	Population modeling of tumor growth curves and the reduced Gompertz model improve prediction of the age of experimental tumors **2020**, 16, e1007178		

5 Population modeling of tumor growth curves and the reduced Gompertz model improve prediction of the age of experimental tumors **2020**, 16, e1007178

4 Population modeling of tumor growth curves and the reduced Gompertz model improve prediction of the age of experimental tumors **2020**, 16, e1007178

3 Population modeling of tumor growth curves and the reduced Gompertz model improve prediction of the age of experimental tumors **2020**, 16, e1007178

2 Population modeling of tumor growth curves and the reduced Gompertz model improve prediction of the age of experimental tumors **2020**, 16, e1007178

1 Population modeling of tumor growth curves and the reduced Gompertz model improve prediction of the age of experimental tumors **2020**, 16, e1007178